Main

Fields of interest:

• Economic Evaluation
• Evidence Synthesis
• Heterogeneity in Cost-Effectiveness
• Statistical & Decision Modeling in Economic Evaluation

Recent publications:

Briggs Andrew, Mihaylova Borislava, Sculpher Mark, Hall Alistair, Wolstenholme Jane, Simoons Maarten, Deckers Jaap, Ferrari Roberto, Remme Willem J, Bertrand Michel, and Fox Kim:
Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study,

Heart, Vol. 93(9), (2007), pp. 1081-6.

Mihaylova Borislava, Briggs Andrew, Armitage Jane, Parish Sarah, Gray Alastair, and Collins Rory on behalf of the Heart Protection Study Collaborative Group:
Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people,
BMJ, Vol. 333(7579), (2006), pp. 1145-8.

Mihaylova Borislava, Briggs Andrew, Armitage Jane, Parish Sarah, Gray Alastair, and Collins Rory on behalf of the Heart Protection Study Collaborative Group:
Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals,
Lancet, Vol. 365(9473), (2005), pp. 1779-85.

Bryant J, Loveman E, Chase D, Mihaylova B, Cave C, Gerard K, Milne R:
The clinical effectiveness and cost effectiveness of the use of human growth hormones in adults,
Vol. 6(19), (2002), pp. 1-96.

Bryant J, Cave C, Mihaylova B, Chase D, McIntyre L, Gerard K, and Milne R:
Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation,
Health Technol Assess, Vol. 6(18), (2002), pp. 1-168.